Edward Jr. Lang

Ed brings more than 20 years of experience in the biotechnology industry and as Chief Business Officer oversees business development, communications and investor relations. He is also building AnHeart’s initial commercial capabilities. Ed has a deep knowledge of corporate strategy, a proven track record of raising capital, and extensive experience in launching cancer medicines.
Prior to joining AnHeart, Ed served as Chief Business Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. Ed previously served as Vice President, Corporate Affairs at Juno Therapeutics, acquired by Celgene. Prior to Juno he spent 13 years at Genentech supporting the approval and launch of 15 new medicines.
Speaking In
3:00 PM - 4:00 PM
Wednesday, June 7
This panel will discuss the evolving landscape of immunotherapy in solid tumors, with a focus on…